# DEB-TACE+HAIC vs. HAIC for Large HCC

> **NCT05263219** · PHASE3 · UNKNOWN · sponsor: **Second Affiliated Hospital of Guangzhou Medical University** · enrollment: 230 (estimated)

## Conditions studied

- Unresectable Hepatocellular Carcinoma

## Interventions

- **PROCEDURE:** dTACE-HAIC
- **PROCEDURE:** HAIC
- **DRUG:** dTACE-HAIC protocol
- **DRUG:** HAIC protocol

## Key facts

- **NCT ID:** NCT05263219
- **Lead sponsor:** Second Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-10
- **Primary completion:** 2026-02-09
- **Final completion:** 2026-02-09
- **Target enrollment:** 230 (ESTIMATED)
- **Last updated:** 2023-06-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05263219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05263219, "DEB-TACE+HAIC vs. HAIC for Large HCC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05263219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*